Effect of sacubitril/valsartan on the hypertensive heart in continuous light-induced and lactacystin-induced pre-hypertension: Interactions with the renin-angiotensin-aldosterone system.

[1]  Said Nabil.  Comparison of International Guidelines for Managing Chronic Heart Failure with Reduced Ejection Fraction. , 2023, Current problems in cardiology.

[2]  C. Deng,et al.  Sacubitril/valsartan reduces susceptibility to atrial fibrillation by improving atrial remodeling in spontaneously hypertensive rats. , 2023, European journal of pharmacology.

[3]  Muhammad Haseeb,et al.  Comparison of Efficacy and Safety of Angiotensin Receptor-Neprilysin Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction: A Meta-Analysis , 2023, Cureus.

[4]  L. Leinwand,et al.  Regression of cardiac hypertrophy in health and disease: mechanisms and therapeutic potential , 2023, Nature Reviews Cardiology.

[5]  K. Kamińska,et al.  Neprilysin Inhibition in the Prevention of Anthracycline-Induced Cardiotoxicity , 2023, Cancers.

[6]  F. Simko,et al.  Melatonin as a Potential Approach to Anxiety Treatment , 2022, International journal of molecular sciences.

[7]  R. Reiter,et al.  Lactacystin-induced kidney fibrosis: Protection by melatonin and captopril , 2022, Frontiers in Pharmacology.

[8]  B. Bozkurt,et al.  Neprilysin Inhibitors in Heart Failure , 2022, JACC. Basic to translational science.

[9]  Š. Zórad,et al.  Sacubitril/Valsartan and Ivabradine Attenuate Left Ventricular Remodelling and Dysfunction in Spontaneously Hypertensive Rats: Different Interactions with the Renin–Angiotensin–Aldosterone System , 2022, Biomedicines.

[10]  M. Tetti,et al.  Aldosterone as a Mediator of Cardiovascular Damage. , 2022, Hypertension.

[11]  S. Rosales‐Corral,et al.  Melatonin: A mitochondrial resident with a diverse skill set. , 2022, Life sciences.

[12]  F. Simko,et al.  Commentary: Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells , 2022, Frontiers in Pharmacology.

[13]  Peili Bu,et al.  Lcz696 Alleviates Myocardial Fibrosis After Myocardial Infarction Through the sFRP-1/Wnt/β-Catenin Signaling Pathway , 2021, Frontiers in Pharmacology.

[14]  F. Simko,et al.  Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers: potential allies in the COVID-19 pandemic instead of a threat? , 2021, Clinical science.

[15]  L. Paulis,et al.  Renin–Angiotensin–Aldosterone System: Friend or Foe—The Matter of Balance. Insight on History, Therapeutic Implications and COVID-19 Interactions , 2021, International journal of molecular sciences.

[16]  Yingxuan Zhang,et al.  Sacubitril/Valsartan Reduces Fibrosis and Alleviates High-Salt Diet-Induced HFpEF in Rats , 2021, Frontiers in Pharmacology.

[17]  C. Sumners,et al.  Correcting the imbalanced protective RAS in COVID-19 with angiotensin AT2-receptor agonists. , 2020, Clinical science.

[18]  S. Miura,et al.  Sacubitril/Valsartan Inhibits Cardiomyocyte Hypertrophy in Angiotensin II-Induced Hypertensive Mice Independent of a Blood Pressure-Lowering Effect , 2020, Cardiology research.

[19]  M. Stowasser,et al.  Effects of Ramipril on the Aldosterone/Renin Ratio and the Aldosterone/Angiotensin II Ratio in Patients With Primary Aldosteronism , 2020, Hypertension.

[20]  Jiarui Jing,et al.  Constant Light Exerted Detrimental Cardiovascular Effects Through Sympathetic Hyperactivity in Normal and Heart Failure Rats , 2020, Frontiers in Neuroscience.

[21]  Neeru M. Sharma,et al.  Central angiotensin II-Protein inhibitor of neuronal nitric oxide synthase (PIN) axis contribute to neurogenic hypertension. , 2020, Nitric oxide : biology and chemistry.

[22]  M. Tetti,et al.  Renin-Angiotensin-Aldosterone System Triple-A Analysis for the Screening of Primary Aldosteronism. , 2019, Hypertension.

[23]  Tongda Xu,et al.  Effects of the Angiotensin‐Receptor Neprilysin Inhibitor on Cardiac Reverse Remodeling: Meta‐Analysis , 2019, Journal of the American Heart Association.

[24]  M. Volpe,et al.  Effects of dual angiotensin type 1 receptor/neprilysin inhibition vs. angiotensin type 1 receptor inhibition on target organ injury in the stroke-prone spontaneously hypertensive rat , 2018, Journal of hypertension.

[25]  H. Krum,et al.  Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction. , 2018, International journal of cardiology.

[26]  M. Gyöngyösi,et al.  Low- and High-renin Heart Failure Phenotypes with Clinical Implications. , 2018, Clinical chemistry.

[27]  R. Reiter,et al.  Mitochondria: Central Organelles for Melatonin′s Antioxidant and Anti-Aging Actions , 2018, Molecules.

[28]  R. Reiter,et al.  Effect of Melatonin on the Renin-Angiotensin-Aldosterone System in l-NAME-Induced Hypertension , 2018, Molecules.

[29]  Š. Zórad,et al.  Lactacystin-Induced Model of Hypertension in Rats: Effects of Melatonin and Captopril , 2017, International journal of molecular sciences.

[30]  D. Kitzman,et al.  Cellular basis of angiotensin-(1-7)-induced augmentation of left ventricular functional performance in heart failure. , 2017, International journal of cardiology.

[31]  B. Rowe,et al.  Roles of Angiotensin Peptides and Recombinant Human ACE2 in Heart Failure. , 2017, Journal of the American College of Cardiology.

[32]  A. Ferreira,et al.  New insights into the elucidation of angiotensin‐(1–7) in vivo antiarrhythmic effects and its related cellular mechanisms , 2016, Experimental physiology.

[33]  R. Reiter,et al.  Elevated heart rate and nondipping heart rate as potential targets for melatonin: a review , 2016, Journal of pineal research.

[34]  S. Miura,et al.  LCZ696, an angiotensin receptor–neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin‐induced diabetic mice , 2016, European journal of heart failure.

[35]  J. McMurray.  Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances , 2015, European journal of heart failure.

[36]  M. Vatta,et al.  Tyrosine Hydroxylase Is Short-Term Regulated by the Ubiquitin-Proteasome System in PC12 Cells and Hypothalamic and Brainstem Neurons from Spontaneously Hypertensive Rats: Possible Implications in Hypertension , 2015, PloS one.

[37]  Akshay S. Desai,et al.  Angiotensin Receptor Neprilysin Inhibition Compared With Enalapril on the Risk of Clinical Progression in Surviving Patients With Heart Failure , 2015, Circulation.

[38]  D. Atar,et al.  Angiotensin Receptor Neprilysin Inhibitor LCZ696 Attenuates Cardiac Remodeling and Dysfunction After Myocardial Infarction by Reducing Cardiac Fibrosis and Hypertrophy , 2015, Circulation. Heart failure.

[39]  Š. Zórad,et al.  Hypertension and Cardiovascular Remodelling in Rats Exposed to Continuous Light: Protection by ACE-Inhibition and Melatonin , 2014, Mediators of inflammation.

[40]  N. Kurumatani,et al.  Association between melatonin secretion and nocturia in elderly individuals: a cross-sectional study of the HEIJO-KYO cohort. , 2014, The Journal of urology.

[41]  C. Zhang,et al.  Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets , 2014, Nature Reviews Cardiology.

[42]  M. Pagano,et al.  Role of the Ubiquitin Proteasome System in the Heart , 2013, Circulation research.

[43]  A. Briones,et al.  Peroxisome proliferator-activated receptor-&ggr; activation reduces cyclooxygenase-2 expression in vascular smooth muscle cells from hypertensive rats by interfering with oxidative stress , 2012, Journal of hypertension.

[44]  V. Pelouch,et al.  Continuous light and L-NAME-induced left ventricular remodelling: different protection with melatonin and captopril , 2010, Journal of hypertension.

[45]  O. Pechanova,et al.  Effect of nuclear factor kappa B inhibition on L-NAME-induced hypertension and cardiovascular remodelling , 2010, Journal of hypertension.

[46]  C. de Ciuceis,et al.  Effects of Melatonin and Pycnogenol on Small Artery Structure and Function in Spontaneously Hypertensive Rats , 2010, Hypertension.

[47]  O. Pechanova,et al.  Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment , 2009, Journal of pineal research.

[48]  M. Young.  Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation , 2008, Current opinion in nephrology and hypertension.

[49]  L. Paulis,et al.  LA419, a novel nitric oxide donor, prevents cardiac remodeling via the endothelial nitric oxide synthase pathway: NO donors as a means of antiremodeling. , 2007, Hypertension.

[50]  L. Paulis,et al.  Melatonin as a potential antihypertensive treatment , 2007, Journal of pineal research.

[51]  G. Mazzocchi,et al.  Stimulation of endogenous nitric oxide production is involved in the inhibitory effect of adrenomedullin on aldosterone secretion in the rat , 2001, Peptides.

[52]  K. Weber.  Fibrosis and hypertensive heart disease , 2000, Current opinion in cardiology.

[53]  A. Samarel,et al.  Sarcomeric myosin heavy chain is degraded by the proteasome , 1999, Cell and Tissue Research.

[54]  P. Mulrow.  Angiotensin II and aldosterone regulation , 1999, Regulatory Peptides.

[55]  A. Goldberg,et al.  Lactacystin and clasto-Lactacystin β-Lactone Modify Multiple Proteasome β-Subunits and Inhibit Intracellular Protein Degradation and Major Histocompatibility Complex Class I Antigen Presentation* , 1997, The Journal of Biological Chemistry.

[56]  C. Enwemeka,et al.  A simplified method for the analysis of hydroxyproline in biological tissues. , 1996, Clinical biochemistry.

[57]  F. Simko.  Left ventricular hypertrophy regression as a process with variable biological implications. , 1996, The Canadian journal of cardiology.

[58]  R. Reiter,et al.  Experimental models of melatonin-deficient hypertension. , 2013, Frontiers in bioscience.

[59]  L. Paulis,et al.  Effect of captopril and melatonin on fibrotic rebuilding of the aorta in 24 hour light-induced hypertension. , 2013, Physiological research.

[60]  D. Rigel,et al.  Echocardiographic examination in rats and mice. , 2009, Methods in molecular biology.

[61]  M. Vinciguerra,et al.  Aldosterone activates NF-kappaB in the collecting duct. , 2009, Journal of the American Society of Nephrology : JASN.

[62]  N. Zisapel,et al.  Impaired nocturnal melatonin secretion in non-dipper hypertensive patients. , 2003, Blood pressure.